Dataset Information

Data-independent acquisition (DIA) based quantitative proteomic analysis of oral cancer tissue samples

ABSTRACT: Oral cancer ranks as the 7th most common cancer worldwide with an increasing incidence and mortality rate. Currently, immunotherapy has emerged as a promising approach for cancer treatment including in head and neck cancer, characterised by prolonged survival rate. We conducted a data-independent acquisition (DIA) based quantitative proteomics analysis to identify the differentially expressed proteins in oral cancer patients. The LC-MS/MS analysis resulted in the identification of 29459 precursors corresponding to 3429 proteins. Among these 1197 proteins showed significant differential expression between control and oral cancer tissue samples. Additionally, our downstream bioinformatics analysis identified 185 proteins with a potential role in immune regulation.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Oral Cancer Cell

DISEASE(S): Oral Cavity Cancer

SUBMITTER: Keshava Prasad T. S.

LAB HEAD: T. S. Keshava Prasad

PROVIDER: PXD052432 | Pride | 2025-06-11

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	DIA_TP.pg_matrix.tsv	Tabular
	DIA_TP.pr_matrix.tsv	Tabular
	OSCC_Tissue_DIA_TP_Normal_R1.raw	Raw
	OSCC_Tissue_DIA_TP_Normal_R2.raw	Raw
	OSCC_Tissue_DIA_TP_Normal_R3.raw	Raw

Items per page:

1 - 5 of 9

Publications

Proteomic profiling of oral squamous cell carcinoma tissues reveals altered immune-related proteins: implications for personalized therapy.

Palollathil Akhina A Babu Sreeranjini S Abhinand Chandran S CS Mathew Rohan Thomas RT Vijayakumar Manavalan M Prasad Thottethodi Subrahmanya Keshava TSK

Expert review of proteomics 20241112 11

<h4>Objectives</h4>Oral squamous cell carcinoma poses a substantial global health challenge marked by rising mortality rate. Recently, immunotherapy has shown promising results in cancer management by enhancing immune response. Thus, identifying additional immune-related markers is critical for advancing immunotherapy treatments.<h4>Methods</h4>Data-independent acquisition (DIA) mass spectrometry approach was used to explore differentially expressed immune-related proteins in oral cancer tissues ...[more]

PMID: 39523852

Similar Datasets

Project description:Patients with oral preneoplastic lesion (OPL) have high risk of developing oral cancer. Although certain risk factors such as smoking status and histology are known, our ability to predict oral cancer risk remains poor. The study objective was to determine the value of gene expression profiling in predicting oral cancer development. Gene expression profile was measured in 86 of 162 OPL patients who were enrolled in a clinical chemoprevention trial that used the incidence of oral cancer development as a prespecified endpoint. The median follow-up time was 6.08 years and 35 of the 86 patients developed oral cancer over the course. Gene expression profiles were associated with oral cancer-free survival and used to develope multivariate predictive models for oral cancer prediction. We developed a 29-transcript predictive model which showed marked improvement in terms of prediction accuracy (with 8% predicting error rate) over the models using previously known clinico-pathological risk factors. Based on the gene expression profile data, we also identified 2182 transcripts significantly associated with oral cancer risk associated genes (P-value<0.01, single variate Cox proportional hazards model). Functional pathway analysis revealed proteasome machinery, MYC, and ribosomes components as the top gene sets associated with oral cancer risk. In multiple independent datasets, the expression profiles of the genes can differentiate head and neck cancer from normal mucosa. Our results show that gene expression profiles may improve the prediction of oral cancer risk in OPL patients and the significant genes identified may serve as potential targets for oral cancer chemoprevention. Gene expression profile was measured in 86 of 162 OPL patients who were enrolled in a clinical chemoprevention trial that used the incidence of oral cancer development as a prespecified endpoint. The median follow-up time was 6.08 years and 35 of the 86 patients developed oral cancer over the course. Gene expression profiles were associated with oral cancer-free survival and used to develope multivariate predictive models for oral cancer prediction.